Focused On-demand Library for Chromodomain-helicase-DNA-binding protein 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q14839

UPID:

CHD4_HUMAN

Alternative names:

ATP-dependent helicase CHD4; Mi-2 autoantigen 218 kDa protein; Mi2-beta

Alternative UPACC:

Q14839; Q8IXZ5

Background:

Chromodomain-helicase-DNA-binding protein 4 (CHD4), also known as ATP-dependent helicase CHD4, plays a pivotal role in DNA remodeling and repair. It is a key component of the NuRD complex, influencing chromatin structure to facilitate transcriptional repression and double-strand break repair. CHD4's ability to bind and distort nucleosomal DNA underscores its significance in maintaining genomic integrity.

Therapeutic significance:

CHD4's involvement in Sifrim-Hitz-Weiss syndrome, characterized by intellectual disability and congenital defects, highlights its potential as a therapeutic target. Understanding CHD4's role could pave the way for innovative treatments for this syndrome and other related genetic disorders.